Clinical Trials Browser

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT07020221 2026-04-03

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase 1 Recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04891289 2026-04-01

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Phase 2 Recruiting

164 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

1,130 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT06608927 2026-04-01

PRISM-1

Phase 3 Active not recruiting

610 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04104672 2026-03-31

ARC-8

Phase 1 Active not recruiting

196 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06360354 2026-03-31

MTAPESTRY 103

Phase 1 Recruiting

350 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

470 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05586516 2026-03-30

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

16 enrolled

Gastrointestinal

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Phase 1 Active not recruiting

9 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06904378 2026-03-30

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

61 enrolled

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

94 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07036380 2026-03-27

TACTIC

Phase 2 Recruiting

75 enrolled

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT07259317 2026-03-27

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT05771480 2026-03-25

TOURMALINE

Phase 3 Active not recruiting

142 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

260 enrolled

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

Clinical Trials

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

DESTINY-BTC01

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

KEYNOTE-966

HCW9218 for Advanced Pancreatic Cancer

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

LAP100

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

RASolute 303

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

9-ING-41 in Patients With Advanced Cancers

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

PANGEA

PRISM-1

ARC-8

MTAPESTRY 103

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

TACTIC

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

TOURMALINE

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)